Skip to main content
Premium Trial:

Request an Annual Quote

New Zealand Funds Research Pairing Ubiquitome, Oxford Nanopore Devices for SARS-CoV-2 Detection

NEW YORK – Ubiquitome said on Tuesday that the New Zealand Health Research Council and Health Ministry is funding research that pairs the company's handheld PCR device and Oxford Nanopore's Flongle sequencer, which can be used for viral genotyping.

The NZ$165,000 ($98,141) grant will fund Massey University researchers aiming to enable one person to screen more than 500 samples and obtain 24 whole genome sequences per day. The research is also validating minimal-extraction and extractionless methods, such as heat treatments, for RNA sample preparation to address the shortage of reagents for SARS-CoV-2 tests.

In the short term, the Liberty16 will be used to disperse screening for SARS-CoV-2 detection, and additional data from the viral genotyping will "support more efficient tracking and tracing of disease contacts," a spokesperson from Ubiquitome said. The data collected will also contribute to longer-term research into disease epidemiology, the spokesperson added.

Ubiquitome's Liberty16 device is a handheld, battery-powered real-time PCR device that can test and relay sample data through an iPhone application. The device is commercialized for research use only in Japan, the US, Canada, the United Kingdom, and Germany. The company also previously said it intends to apply for Emergency Use Authorization in the US.

"What we can do is narrow the time between infection, diagnosis, and source and contact tracing," said Ubiquitome's Chief Scientific Officer Susan Turner. "To achieve this we need technologies that enable widespread access to affordable, line-of-sight diagnostic testing, rapid turnaround of results, and efficient methods to track and trace viral transmission."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.